Key terms

About INZY

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest INZY news

Apr 18 4:55am ET Inozyme management to meet with Piper Sandler by TipRanks Apr 16 2:53pm ET Inozyme management to meet with Piper Sandler by TipRanks Apr 09 7:13am ET Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA) by TipRanks Apr 09 6:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX) by TipRanks Apr 09 5:40am ET Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT) by TipRanks Apr 08 6:52am ET Inozyme Pharma Advances with Promising INZ-701 Trial Results by TipRanks Apr 08 6:36am ET Inozyme announces ‘positive’ results from Phase 1/2 trials of INZ-701 by TipRanks Mar 14 5:47am ET Inozyme Pharma: A Promising Buy Amid Anticipated Clinical Breakthroughs and Financial Stability by TipRanks Mar 13 6:16am ET Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701 by TipRanks Mar 12 3:25pm ET Buy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidence by TipRanks Mar 12 12:45pm ET Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation by TipRanks Mar 12 8:33am ET Inozyme expects cash to fund requirements into 4Q25 by TipRanks Mar 12 8:33am ET Inozyme reports 2023 EPS ($1.37), consensus ($1.34) by TipRanks Feb 06 8:34am ET Inozyme reports inducement grants under Nasdaq listing rule by TipRanks

No recent press releases are available for INZY

INZY Financials

1-year income & revenue

Key terms

INZY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

INZY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Student demonstrators occupy the pro-Palestinian "Gaza Solidarity Encampment" on the West Lawn of Columbia University on April 24, 2024 in New York City.
Michael M. Santiago/Getty Images
What the pro-Palestinian protesters on college campuses actually want
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stagflation fears just hit Wall Street. Now for the next crucial report on prices
Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges 15% on ‘aggressive’ AI spending plans
GettyImages-1159438448 copy.jpg
Lyndon Stratford/iStockphoto/Getty Images
Americans are falling behind on their payments